Is an $84,000 Hepatitis Drug Too Expensive?

The debate over drug prices is heating up as insurers clash with pharmaceutical companies over a wave of expensive new products.

A pharmacist pours Truvada pills back into the bottle at Jack's Pharmacy on November 23, 2010 in San Anselmo, California.
National Journal
Sam Baker
Add to Briefcase
See more stories about...
Sam Baker
May 29, 2014, 1 a.m.

An $84,000 hep­at­it­is drug called Sovaldi is at the cen­ter of a new battle between phar­ma­ceut­ic­al com­pan­ies and in­surers — but the fight is about much more than one drug.

Sovaldi costs $1,000 per day, or $84,000 for a full treat­ment, and cures 90 per­cent of hep­at­it­is C pa­tients who take it. In­surers say the drug is ri­dicu­lously over­priced; the phar­ma­ceut­ic­al in­dustry says it’s a steal.

But the de­bate here isn’t simply about one hep­at­it­is drug. Sovaldi is more like a single skir­mish that has reawakened a broad­er, deep­er, and high­er-stakes cold war over the cost of pre­scrip­tion drugs. Of­fi­cials in both in­dus­tries say that even if Sovaldi’s man­u­fac­turer, Gilead, slashed its prices, the newly in­tens­i­fied battle between in­surers and pharma com­pan­ies wouldn’t re­cede: Sovaldi is just the be­gin­ning.

Sovaldi is a light­ning rod be­cause in­surers and con­sumer ad­voc­ates are afraid it’s a sign of what’s to come. The drug pipeline is full of drugs like Sovaldi, and in­surers say that flood of new, ex­pens­ive products will cause health care spend­ing to skyrock­et.

“I think that this one drug is the ca­nary in the coal mine. It’s one that is out front and one of the first ones we’re see­ing, but there are a lot more down the pipeline,” said Brendan Buck, a spokes­man for Amer­ica’s Health In­sur­ance Plans.

Un­til Sovaldi, the class of products known as “spe­cialty drugs” was mainly tailored to re­l­at­ively rare con­di­tions. The drugs are com­plex, which makes them more ex­pens­ive to pro­duce, driv­ing up the price for con­sumers. And be­cause they treat rarer con­di­tions, there were few­er po­ten­tial cus­tom­ers — an­oth­er factor driv­ing up prices.

Spe­cialty drugs have al­ways been ex­pens­ive. They ac­count for roughly 25 per­cent of U.S. spend­ing on pre­scrip­tion drugs, but just 1 per­cent of all pre­scrip­tions, ac­cord­ing to a newly formed co­ali­tion lob­by­ing for lower prices.

But Sovaldi set off a par­tic­u­lar shock wave largely be­cause it treats a more com­mon ail­ment — some 3 mil­lion people have hep­at­it­is C. They can’t all af­ford an $84,000 course of treat­ment, but still, crit­ics ar­gue, the drug’s large po­ten­tial cus­tom­er base means that a once-nar­row slice of drug spend­ing could ex­plode.

“If this sets a pat­tern for oth­er drugs then we’re really in deep trouble “¦ it’s the com­bin­a­tion of the price and the volume,” said John Roth­er, who helped start the Co­ali­tion for Sus­tain­able Rx Pri­cing. The new or­gan­iz­a­tion, which also in­cludes AARP and oth­er health care ad­voc­ates, launched Wed­nes­day.

The phar­ma­ceut­ic­al in­dustry says crit­ics are miss­ing the point. Yes, Sovaldi is ex­pens­ive, it ar­gues, but that’s be­cause it works. Sovaldi cures about 90 per­cent of pa­tients with a com­mon form of hep­at­it­is C with­in its 12-week course.

Spend­ing $84,000 on a cure might seem ex­pens­ive up front, but it’s a lot more ef­fi­cient in the long run than pay­ing for a string of less ef­fect­ive treat­ments, in­clud­ing hos­pit­al­iz­a­tions that run the risk of com­plic­a­tions, the drug in­dustry says.

A re­port from Optum, a con­sult­ing sub­si­di­ary of United Health­care, agrees. Even very ex­pens­ive drugs can be cost-ef­fect­ive if they work well enough, Optum said in a re­port is­sued be­fore Sovaldi’s price was re­leased.

“It is cer­tainly pos­sible that the com­bin­a­tion of high­er cure rates and re­duced side ef­fects, com­bined with re­duced treat­ment times, may mean even great­er cost-ef­fect­ive­ness in the fu­ture,” Optum’s ana­lysts wrote.

A phar­ma­ceut­ic­al in­dustry of­fi­cial said in­surers’ ef­fort to crack down on Sovaldi and oth­er spe­cialty drugs is short-sighted. The in­sur­ance in­dustry is un­der tre­mend­ous pres­sure to keep premi­ums low, es­pe­cially in the first few years of Obama­care en­roll­ment, and it’s re­act­ing to that pres­sure by steer­ing health pro­viders and con­sumers away from products that are more ex­pens­ive in the short term, the of­fi­cial said — but is run­ning the risk of fore­go­ing longer-term sav­ings.

The ba­sic dy­nam­ics un­der­neath this ten­sion are noth­ing new: Phar­ma­ceut­ic­al com­pan­ies want in­surers to cov­er their drugs, which helps them make money; in­surers want to avoid shelling out tens of thou­sands of dol­lars for ex­pens­ive treat­ments, which helps them make money.

But the Sovaldi dust-up has turned up the in­tens­ity, as in­surers make an ag­gress­ive case that they’re not the ones to blame if rising health care costs drive up premi­ums.

“The real­ity is that the com­pany in this case is ask­ing for a blank check, and we can’t give any­one a blank check in the health care sys­tem “¦ be­cause it will blow up fam­ily budgets, it will blow up state Medi­caid budgets, it will blow up em­ploy­er be­ne­fit costs, and it will wreak hav­oc on the fed­er­al debt,” AHIP Pres­id­ent and CEO Kar­en Ig­nagni said at a re­cent event sponsored by The At­lantic.

What We're Following See More »
SPONSORED BY BARBARA LEE
House Approps Passes AUMF Repeal Amendment
8 minutes ago
THE DETAILS
DRAWS IRE OF WOMEN AGAIN
Trump Posts Crude Tweet About Mika Brzezinski
26 minutes ago
THE LATEST

President Trump is taking heat for another series of tweets, this one aimed at the co-hosts of Morning Joe. “I heard poorly rated @Morning_Joe speaks badly of me (don’t watch anymore),” Trump wrote. “Then how come low I.Q. Crazy Mika, along with Psycho Joe, came … to Mar-a-Lago 3 nights in a row around New Year’s Eve, and insisted on joining me. She was bleeding badly from a face-lift. I said no!” In a tweet, Rep. Lynn Jenkins (R-KS) said of Trump's statement, "This is not okay." NBC public relations chief Mark Kornblau said it's "beneath my dignity to respond to the President of the United States."

Source:
HEAD OF SECURITY TURNED WHITE HOUSE AIDE
House Intel Wants to Interview Trump Bodyguard
38 minutes ago
THE LATEST

"Congressional investigators now want to interview Keith Schiller, President Donald Trump’s longtime bodyguard-turned-White House aide, as part of their investigation into Russian interference in the 2016 presidential campaign, sources familiar with the investigation told ABC News. Schiller, the former head of security for the Trump Organization who now serves as the White House director of Oval Office operations, is one of several Trump associates on the House Intelligence Committee’s witness list in its ongoing investigation into Russian election interference."

Source:
MOSUL NEARLY RECAPTURED
Iraq Says ISIS Is Defeated
39 minutes ago
THE DETAILS

"After eight months of grinding urban warfare, Iraqi government troops on Thursday captured the ruined mosque in Mosul from where Islamic State proclaimed its self-styled caliphate three years ago," and the Iraqi military expect the entire city to be retaken in a matter of days. "Their fictitious state has fallen," said an Iraqi military spokesman.

Source:
BUT WILL BUY HALF OF ITS STORES
Walgreens Won’t Buy Rite Aid
1 hours ago
THE LATEST

"The move puts to death the long-suffering tie-up between Walgreens and Rite Aid, which was originally announced in October 2015 ...The new deal was designed to alleviate the FTC's concerns about the market overlap between Walgreens and Rite Aid and the bolstered bargaining power a full acquisition would have given Walgreens. Rite Aid said it had to ditch the original deal after regulators privately 'led the company to believe that the parties would not have obtained FTC clearance to consummate the merger.'"

Source:
×
×

Welcome to National Journal!

You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.

Login